Intelligent Bio Solutions Inc. (INBS)
| Market Cap | 10.77M |
| Revenue (ttm) | 3.05M |
| Net Income (ttm) | -10.57M |
| Shares Out | 7.32M |
| EPS (ttm) | -2.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 66,639 |
| Open | 1.480 |
| Previous Close | 1.480 |
| Day's Range | 1.450 - 1.497 |
| 52-Week Range | 1.000 - 3.000 |
| Beta | 4.59 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 15, 2025 |
About INBS
Intelligent Bio Solutions Inc., a medical technology company, developing rapid, non-invasive testing, and screening solutions. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse. It also operates biosensor platform for clinical chemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions In... [Read more]
Financial Performance
In 2025, Intelligent Bio Solutions's revenue was $3.05 million, a decrease of -1.90% compared to the previous year's $3.11 million. Losses were -$10.57 million, 4.06% more than in 2024.
Financial StatementsNews
Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies
Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings
Intelligent Bio Solutions to Participate in the Sidoti Micro-Cap Virtual Conference on August 20-21, 2025
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing an...
Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter Revenue with Double-Digit Sequential and Year-Over-Year Growth and Strong Operational Momentum
Company anticipates fiscal fourth quarter sequential and year-on-year revenue growth of approximately 16% Company advanced efforts to secure U.S. FDA 510(k) clearance for planned U.S. market entry and...
Intelligent Bio Solutions Strengthens FDA 510(k) Package with New Cybersecurity and Performance Data Ahead of Planned U.S. Market Launch
FDA response expected within six weeks; Company remains focused on 2025 U.S. expansion FDA response expected within six weeks; Company remains focused on 2025 U.S. expansion
Intelligent Bio Solutions Secures Major Drug Testing Tender with Leading London Transport Operator
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing so...
Intelligent Bio Solutions Inc. Enters Into Agreements to Raise $3.8 Million in Gross Proceeds
Proceeds to Fund Completion of the Company's 510k Filing with the U.S. FDA for its Fingerprint Drug Screening System Proceeds to Fund Completion of the Company's 510k Filing with the U.S. FDA for its ...
Intelligent Bio Solutions to Strengthen FDA 510(k) Submission with New Positive Data Demonstrating Ultra-Precise Fingerprint Sweat Detection and Platform Resilience
Data confirms Company's ability to detect trace sweat volumes at ultra-micro level System demonstrates resilience across diverse conditions NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio ...
Intelligent Bio Solutions Accelerates Global Growth with SmarTest® Patch Agreement, Reinforces U.S. Expansion Path as FDA Approval Remains a Strategic Priority
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing so...
Intelligent Bio Solutions Adds Next-Gen Wearable for Extended Drug Detection to Product Offering, Strengthening Leadership in Non-Invasive Testing
NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing so...
Intelligent Bio Solutions to Present PK Study Data at Association for Diagnostics and Laboratory Medicine 2025 Clinical Lab Expo
Data shows excretion of codeine in fingerprint sweat INBS' System is viable option for non-invasive diagnostic testing NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasda...
Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia
With over 450 accounts across 24 countries, INBS continues to advance the evolution of drug screening technology With over 450 accounts across 24 countries, INBS continues to advance the evolution of ...
Intelligent Bio Solutions Launches In-House Fingerprint Drug Testing Across 20+ Sites for Major Australian Waste Operator, Accelerating APAC Expansion
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing so...
Intelligent Bio Solutions Expands U.S. Forensic Market Presence, Seeks FDA Clearance for Breakthrough Fingerprint Drug Testing
SMARTOX has deployed over 50 of INBS' Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more than 1,500 tests in 2024 alone
Intelligent Bio Solutions to Showcase Fingerprint Drug Testing at RISE25 Conference from May 28-31, Supporting Innovation in U.S. Forensic Drug Testing
INBS to participate with U.S. distribution partner SMARTOX at RISE25, the leading U.S. conference on addiction, mental health, and justice innovation which draws over 7,000 attendees annually
Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment
Completion of 160 tests conducted in less than 90 minutes demonstrates a level of speed and efficiency beyond the limits of traditional testing approaches Completion of 160 tests conducted in less tha...
Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing
Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing surges Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing...
Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements
20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nin...
Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion
Arabic, Italian, and Spanish-language websites unlock commercial access to regions representing over 1.4 billion people Multilingual rollout aligns with product readiness and accelerates international...
Intelligent Bio Solutions Expands Global Reach with Latin American Spanish Language Integration into Drug Screening System
Company expands Intelligent Fingerprinting Drug Screening System multilingual capabilities to meet growing demand across Latin American Spanish-speaking markets
Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing s...
Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing s...
Intelligent Bio Solutions Highlights Continued Expansion with Strategic Partnership in Spain and Andorra
INBS set to capitalize on growing Spanish Drug Testing Market, anticipated to reach $448 million by 2030 Major Spanish accounts currently require 1,000 drug testing cartridges per month NEW YORK, Marc...
Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry
Company's 6 th U.S. patent adds to comprehensive IP portfolio protecting its unique drug screening technology
Intelligent Bio Solutions' FDA Clearance Process Remains on Track for 2025 U.S. Launch
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing s...
Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing s...